Search results
Results from the WOW.Com Content Network
Sun Pharmaceutical Industries Ltd. was established by Dilip Shanghvi in 1983 in Calcutta, West Bengal with five psychiatry products and a two-person marketing team. Today it is ranked number one in share of prescriptions with 12 classes of doctors in India and a market leader in Psychiatry, Neurology, Cardiology, Orthopaedics, Gastroenterology, Nephrology, Diabetology, Dermatology, Urology ...
The Chicago metropolitan area – also known as "Chicagoland" – is the metropolitan area associated with the city of Chicago, Illinois, and its suburbs. [2] With an estimated population of 9.4 million people, [3] it is the third largest metropolitan area in the United States [4] and the region most connected to the city through geographic ...
This is an accepted version of this page This is the latest accepted revision, reviewed on 23 January 2025. Indian Businessman Dilip Shanghvi Born (1955-10-01) 1 October 1955 (age 69) Amreli, Gujarat, India Alma mater Bhawanipur Education Society College, University of Calcutta Occupation(s) Founder and MD of Sun Pharmaceuticals Spouse Vibha Shanghvi Children 2 Dilip Shanghvi (born 1 October ...
For premium support please call: 800-290-4726 more ways to reach us
On 7 April 2014, India-based Sun Pharmaceutical and Japan-based Daiichi Sankyo jointly announced the sale of the entire 63.4% share of Ranbaxy from Daiichi Sankyo to Sun Pharmaceutical in a $4 billion all-share deal. Under these agreements, shareholders of Ranbaxy were to receive a 0.8 share of Sun Pharmaceutical for each share of Ranbaxy. [3]
This "formally initiates the litigation process under the Hatch-Waxman Act and triggers a 30-month stay of any potential FDA approval for Sun Pharma's ANDA," Mayne Pharma said in a statement.
Get AOL Mail for FREE! Manage your email like never before with travel, photo & document views. Personalize your inbox with themes & tabs. You've Got Mail!
In 2010, Sun Pharmaceuticals of India acquired a majority stake in the company. [6] On 22 March 2012, the company's shares were re-listed on the NYSE. In 2013, Sun Pharmaceuticals attempted to buy the remaining shares in the company (it owns 69% stake), but as the company's financial performance improved, shareholders rejected the offer and the company remained publicly listed.